JP2023528859A5 - - Google Patents
Info
- Publication number
- JP2023528859A5 JP2023528859A5 JP2022574270A JP2022574270A JP2023528859A5 JP 2023528859 A5 JP2023528859 A5 JP 2023528859A5 JP 2022574270 A JP2022574270 A JP 2022574270A JP 2022574270 A JP2022574270 A JP 2022574270A JP 2023528859 A5 JP2023528859 A5 JP 2023528859A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- solvate
- isomer
- hydrate
- modulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010486394.1 | 2020-06-01 | ||
| CN202010486394 | 2020-06-01 | ||
| CN202010947590 | 2020-09-10 | ||
| CN202010947590.4 | 2020-09-10 | ||
| CN202110587528.3 | 2021-05-27 | ||
| CN202110587528 | 2021-05-27 | ||
| PCT/CN2021/097583 WO2021244505A1 (zh) | 2020-06-01 | 2021-06-01 | 新型吡嗪化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023528859A JP2023528859A (ja) | 2023-07-06 |
| JP2023528859A5 true JP2023528859A5 (enExample) | 2024-05-31 |
| JP7777544B2 JP7777544B2 (ja) | 2025-11-28 |
Family
ID=78830119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574270A Active JP7777544B2 (ja) | 2020-06-01 | 2021-06-01 | 新規ピラジン化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12600714B2 (enExample) |
| EP (1) | EP4159731A4 (enExample) |
| JP (1) | JP7777544B2 (enExample) |
| KR (1) | KR20230019444A (enExample) |
| CN (1) | CN115698000B (enExample) |
| AU (1) | AU2021284676A1 (enExample) |
| BR (1) | BR112022022220A2 (enExample) |
| CA (1) | CA3179395A1 (enExample) |
| MX (1) | MX2022013397A (enExample) |
| TW (1) | TWI845843B (enExample) |
| WO (1) | WO2021244505A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4373817B1 (en) * | 2021-07-20 | 2025-05-21 | Astrazeneca AB | Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5108000A (en) | 1999-06-10 | 2001-01-02 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
| WO2003045924A1 (en) * | 2001-11-21 | 2003-06-05 | Pharmacia & Upjohn Company | Substituted aryl 1,4-pyrazine derivatives |
| JP5364159B2 (ja) * | 2009-05-08 | 2013-12-11 | アステラス製薬株式会社 | ジアミノへテロ環カルボキサミド化合物 |
| WO2013108754A1 (ja) | 2012-01-17 | 2013-07-25 | アステラス製薬株式会社 | ピラジンカルボキサミド化合物 |
| CA2975072A1 (en) * | 2015-01-28 | 2016-08-04 | Astellas Pharma Inc. | Method for producing pyrazinecarboxamide compound and synthetic intermediate thereof |
| MA42623A (fr) | 2015-06-02 | 2018-06-20 | Pharmacyclics Llc | Inhibiteurs de la tyrosine kinase de bruton |
| WO2018103663A1 (zh) * | 2016-12-09 | 2018-06-14 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的吡嗪甲酰胺类化合物及包含该化合物的组合物及其用途 |
| EP3656769B1 (en) | 2017-07-19 | 2023-01-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Aryl-phosphorus-oxygen compound as egfr kinase inhibitor |
-
2021
- 2021-06-01 BR BR112022022220A patent/BR112022022220A2/pt unknown
- 2021-06-01 TW TW110119810A patent/TWI845843B/zh active
- 2021-06-01 JP JP2022574270A patent/JP7777544B2/ja active Active
- 2021-06-01 WO PCT/CN2021/097583 patent/WO2021244505A1/zh not_active Ceased
- 2021-06-01 MX MX2022013397A patent/MX2022013397A/es unknown
- 2021-06-01 EP EP21817710.3A patent/EP4159731A4/en active Pending
- 2021-06-01 US US17/917,435 patent/US12600714B2/en active Active
- 2021-06-01 CN CN202180039487.2A patent/CN115698000B/zh active Active
- 2021-06-01 CA CA3179395A patent/CA3179395A1/en active Pending
- 2021-06-01 KR KR1020227044988A patent/KR20230019444A/ko active Pending
- 2021-06-01 AU AU2021284676A patent/AU2021284676A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3849534T3 (fi) | Yhdistelmähoidot | |
| MX2024010140A (es) | Nuevos metodos. | |
| KR102375262B9 (en) | GLP-1 Pharmaceutical composition comprising sustained release-microsphere comprising GLP-1 Analogue or pharmaceutically acceptable salt thereof | |
| IL311376B2 (en) | Azetidine and pyrrolidine parp1 inhibitors and uses thereof | |
| CN110036005A (zh) | 酰胺衍生物及其在药物中的应用 | |
| JP2015537009A5 (enExample) | ||
| JP2018168191A5 (enExample) | ||
| JP2007514005A5 (enExample) | ||
| JP2023076465A5 (enExample) | ||
| JP2020521797A5 (enExample) | ||
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| JP2023550149A5 (enExample) | ||
| MX2023001671A (es) | Procedimiento y compuesto para su uso en el tratamiento y/o prevención de la netosis. | |
| IL307992A (en) | Parasitic formulations containing isoxazoline and methods for treating blepharitis | |
| JP2021525752A5 (enExample) | ||
| JP2005507892A5 (enExample) | ||
| PH12021550218A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| SA521422467B1 (ar) | مركبات هالو-آلِّيلامين واستخدامها | |
| JP2022552520A5 (enExample) | ||
| JP2004532828A5 (enExample) | ||
| JP2022517902A5 (enExample) | ||
| JP2018505218A5 (enExample) | ||
| JP2025507472A5 (enExample) | ||
| IL295014B1 (en) | A pharmaceutical preparation containing 5-(-6,3-dibromo-H9-carbazol-9-yl)-N,N,N-trimethylpentan-1-iminium or the pharmaceutical salt is suitable for use in the treatment of angiolipoma | |
| JP2020527138A5 (enExample) |